ReviewFrontiers in oncology2026
Immune microenvironment evolution across the serrated neoplasia pathway and its relevance to immunotherapy.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The serrated neoplasia pathway is a major molecular route to colorectal carcinogenesis, accounting for approximately 15%-30% of sporadic colorectal cancers and characterized by early BRAF V600E mutation, CpG island methylator phenotype, and distinct histopathologic features. Although immune checkpoint inhibitors have shown clear efficacy in MSI-H/dMMR colorectal cancer, serrated pathway-associated tumors remain highly heterogeneous in their molecular evolution and immune microenvironments. This heterogeneity may be associated with diverse immune phenotypes and potentially variable responsiveness to immunotherapy. Emerging evidence suggests that changes in the immune microenvironment may begin before invasive transformation. In sessile serrated lesions, early immune surveillance features, including intraepithelial CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.